The authors disclose the following financial relationships within the past 3 years: Following a competitive bid and request involving all TMS manufacturers at the time of trial initiation, Neuronetics Inc. was selected and loaned the TMS devices, head holders, and coils for the trial and allowed use of the safety Investigational Device Exemption for their device. Neuronetics did not provide any financial support for the study which was funded by the NIMH. Potential conflicts are reported over the past 3 years. Dr. McDonald is presently an unpaid consultant to NeoStim. Dr. Holtzheimer reports consulting fees from St. Jude Medical Neuromodulation, AvaCat Consulting, and Tetragenex, and is an unpaid consultant to NeoStim. Drs. McDonald and Holtzheimer are faculty at Emory University which holds a patent on TMS technology. Neither received royalties or is involved in the development or promotion of this patent. Dr. Lisanby reports research grants, speaking fees, or advisory board work with Neuronetics, Advanced Neuromodulatory Systems, Brainsway, and Cyberonics. Dr. Lisanby has a patent application with Columbia University on neuromodulation technology for which she receives no royalties or compensation. Dr. Avery has received research support from Neuronetics and Takeda, has been a consultant for Neuronetics and has been on the speaker's bureau for Eli Lilly, Takeda and Forest Pharmaceuticals. Dr. Nahas reports past and current research grants, speaking fees or consulting work with Cyberonics, Neuronetics, MECTA Corporation, and Medtronic. Dr. Nahas has acted as an unpaid consultant for Neuropace. Dr. Sackeim received consultant fees from MECTA Corporation and Cyberonics. Dr. George received consultant fees from PureTech Ventures and reports research grants, speaking fees, or advisory work with Brainsway, Mecta Corporation, Neuronetics, Cephos, NeoStim and NeoSync, Brainsonix, Cyberonics, and Cephos. Dr. George is faculty at MUSC which has two patent applications in Dr. George's name combining MRI and TMS.
Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression†
Article first published online: 2 SEP 2011
© 2011 Wiley Periodicals, Inc.
Depression and Anxiety
Volume 28, Issue 11, pages 973–980, November 2011
How to Cite
McDonald, W. M., Durkalski, V., Ball, E. R., Holtzheimer, P. E., Pavlicova, M., Lisanby, S. H., Avery, D., Anderson, B. S., Nahas, Z., Zarkowski, P., Sackeim, H. A. and George, M. S. (2011), Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress. Anxiety, 28: 973–980. doi: 10.1002/da.20885
- Issue published online: 10 NOV 2011
- Article first published online: 2 SEP 2011
- Manuscript Accepted: 10 JUL 2011
- Manuscript Revised: 5 JUL 2011
- Manuscript Received: 6 APR 2011
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.